Sunday, December 1, 2019

Biocon Biologics to reduce the cost of human insulin and cancer drugs

The Biocon subsidiary will chart a path that ensures high volumes and lowcosts, unlike competitors, Christiane Hamacher, chief executive of Biocon Biologics told ET. https://ift.tt/2RcdZVI https://ift.tt/eA8V8J
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

JD reports Q4 revenue up 13% YoY to ~$48B, its fastest growth in three years and above est., net income up 100%+ to ~$1.4B, as Chinese consumer spending rises (Bloomberg)

Bloomberg : JD reports Q4 revenue up 13% YoY to ~$48B, its fastest growth in three years and above est., net income up 100%+ to ~$1.4B, a...